Common Sense Oncology shared a post on X:
“In an important development for the oncology community, The Lancet Oncology and several other specialty journals within The Lancet family have come together to advocate for greater transparency in clinical trials reporting.
The Comment, published today, highlights key areas where the journals will apply enhanced scrutiny of submitted manuscripts in order to align with the highest standards of scientific rigour. The aim is to ensure articles are written in a way that enables readers to make informed clinical decisions in the best interest of patients.
These changes align closely with Common Sense Oncology’s “Principles for the design, analysis, and reporting of phase 3 randomised clinical trials,” published a year ago in The Lancet Oncology. They will help increase transparency in clinical trial reporting, ultimately benefiting patients, and we call on other oncology journals to adopt these more rigorous editorial review standards.”
Title: Greater transparency for oncology clinical trials reporting
Authors: David Collingridgea, Allison Landmanb, Robert Brierleyc, Claudia Schaeferd, Jie Caie, Emma Graingerf, Sonia Muliyilg, Lan-Lan Smith
Read the paper
More posts featuring Common Sense Oncology